Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy.
The clinical efficacy of immunotherapy, either by high dose sublingual-swallow therapy (SLIT) or subcutaneous immunotherapy (SCIT), has been demonstrated in patients with pollinosis but few studies have been carried out analysing differences in these treatments in terms of an improvement of clinical and allergic phlogosis parameters. The aim of this double-blind placebo-controlled study is to investigate the efficacy of high dose SLIT and SCIT using a purified standardized Juniperus ashei extract in a population of allergic patients monosensitized to cypress. Forty patients with cypress-allergic rhino conjunctivitis were administered therapeutic or placebo SLIT or SCIT for 12 months. Laboratory parameters were studied, namely the eosinophil cationic protein (ECP) level in nasal lavage and in serum, as well as the number of eosinophils (EOS) in peripheral blood and in nasal lavage and the level of eosinophil chemotactic activity (ECA). These parameters were correlated with clinical symptoms, evaluated by means of the clinical symptoms score (CSS). After SCIT and SLIT the levels of ECP and ECA were reduced in nasal lavage. We also observed a significant reduction in the values of ECP in serum in the patients treated with SLIT. EOS were unchanged in peripheral blood, but significantly reduced in nasal lavage. These data were in accordance with the improvement of clinical symptoms, supported by the close correlation between CSS and laboratory parameters. Our data confirm a clinical improvement correlated with a decline in inflammation parameters after one year of immunotherapy, supporting the hypothesis that treatment with a major allergen of cypress is able to change the course of allergic rhinitis.
Ventura
M T
MT
Department of Internal Medicine, Immunology and Infectious Diseases MIDIM, University of Bari Medical School, Policlinico, Bari, Italy. mt.ventura@allergy.uniba.it
Carretta
A
A
Tummolo
R A
RA
Buquicchio
R
R
Arsieni
A
A
Murgia
N
N
D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D052179:Antigens, Plant / Q000008:administration & dosage* / Q000276:immunology; D002631:Chemotactic Factors, Eosinophil / Q000378:metabolism; D002634:Chemotaxis, Leukocyte; D003233:Conjunctivitis, Allergic / Q000276:immunology / Q000628:therapy*; D029781:Cupressus / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods*; D004311:Double-Blind Method; D047150:Eosinophil Cationic Protein / Q000097:blood; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D017817:Nasal Lavage Fluid / Q000166:cytology / Q000276:immunology; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D052179:Antigens, Plant; D002631:Chemotactic Factors, Eosinophil; D018836:Inflammation Mediators; D047150:Eosinophil Cationic Protein; C479220:RNASE3 protein, human